AzTrials
AzTrials

StrokeNCT06999122

Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

An observational study of Stroke and Hemorrhagic Stroke, run by EMVision Medical Devices Ltd at 8 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic… Read more about this study

Who is it for?
Ages 22 years and older
Conditions the study is for
Stroke, Hemorrhagic Stroke
What is being tested?
Brain Scan
How many people
300 participants
Where
8 sitesin 2 countries
Study dates
26 Mar 2025to 28 Nov 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 300 subjects across two study arms

Who may be able to join

  • Adults ≥22 years of age
  • Observable acute neurological deficit suspected to be stroke and within 24 hours of symptom onset
  • The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient
  • CT or MRI brain imaging following clinical evaluation per standard of care
  • Head size deemed suitable for scanning with the EMVision emu™ Brain Scanner -

Who cannot join

  • Has received treatment for current (suspected) stroke event prior to initial CT/MRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)
  • In-patient for a neurological condition prior to suspected stroke onset
  • In-patient in intensive care unit prior to suspected stroke onset
  • Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography
  • Presence of any implanted electro-stimulating devices in the head and neck
  • Presence of any metallic implants in the cranial vault or surrounding bones/tissue (Note that metallic objects distant from the scan area, such as dental implants, nasal piercing etc., are acceptable)
Show all 11Show fewer
  • Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device
  • Inability to wear the investigational device (skin lesions on scalp, obvious recent blunt or penetrating injury to head, previous intracranial surgeries, neck injury etc.)
  • Unable to lie still for the duration of the scan
  • Pregnant or breastfeeding
  • Any other condition or symptoms preventing the participant from entering the study, according to the investigator´s judgment -

Trial locations and contacts

8 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Christian Wight, PhD contact

61 (0) 490 109 797

cwight@emvision.com.au

Sadie Burnham contact

7742078910

sburnham@vastrax.com

8 sites in 2 countries

United States6 sites, 6 recruiting
  • Memorial Hermann Memorial City Medical Center

    Houston, Texas, 77024

    Glenda Torres, 713-500-6153, Glenda.L.Torres@uth.tmc.edu

    Aaron M Gusdon, PhD

    Recruiting
  • UTHealth

    Houston, Texas, 77030

    Glenda Torres, 713-500-6153, Glenda.L.Torres@uth.tmc.edu

    Aaron Gusdon, PhD

    Recruiting
  • Mayo Jacksonville

    Jacksonville, Florida, 32224

    Ewa Szymkiewicz, 904-953-3219, Szymkiewicz.Ewa@mayo.edu

    William Freeman, PhD

    Recruiting
  • UCLA

    Los Angeles, California, 90095

    Sucheta Waghmare, 310-206-5501, SWaghmare@mednet.ucla.edu

    May Nour, MD, PHD

    Recruiting
  • Mount Sinai West

    New York, New York, 10019

    Megha Dhillon, 212-241-3400, Megha.Dhillon@mountsinai.org

    Hazem Shoirah, MD

    Recruiting
  • Mount Sinai Health System

    New York, New York, 10029

    Megha Dhillon, 212-241-3400, Megha.Dhillon@mountsinai.org

    Hazem Shoirah, MD

    Recruiting

Other trials in United States

Australia2 sites, 2 recruiting
  • Liverpool Hospital

    Liverpool, New South Wales, 2170

    Jasmeen Khan, 0428 292 184, Jasmeen.Khan@health.nsw.gov.au

    Dennis Cordato, PhD

    Recruiting
  • Royal Melbourne Hospital

    Parkville, Victoria, 3050

    Christine Shin, 03 9342 4413, SooJeong.Shin@mh.org.au

    Angela Dos Santos, MD

    Recruiting

Other trials in Australia

About this study

Official title: Multi-Center, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.

EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.

Read the detailed description

This clinical investigation is a paired diagnosis, diagnostic performance study intended to quantify the accuracy of the emu™ Brain Scanner's diagnostic output in comparison to current gold-standard practices including multi-modal neuroimaging by CT and/or MRI.

Any adult with neurological deficit suspected to be stroke shall be considered as potentially eligible for the study. Potential participant's eligibility for the study is determined via screening evaluation which includes a review of available demographic and medical history information against the study's inclusion and exclusion criteria, as well as a head size assessment using provided gauges to confirm that their head would fit within the emu™ Brain Scanner. If the screening evaluation finds that the participant is eligible for the study then the investigator proceeds with the informed consent process. This activity occurs in parallel with the investigational site's standard practices for stroke patient management, ensuring no delay in these patients' care.

Regardless of study participation, participants will receive the complete standard of care diagnostic workflow in accordance with applicable national and international guidelines, as well as practices established at the investigational site. The standard of care diagnostic workflow is centered around acute baseline multi-modal CT imaging (and in some instances MRI). Directly following or before this imaging, and without delaying subsequent treatment, a scan is completed with the emu™ Brain Scanner to allow timely coordination between the investigational emu™ Brain Scan result and the reference standard CT/MRI imaging. If the attending physician perceives any potential risk of delaying treatment of the patient then that patient is strictly exclude from the study, entirely at the attending physician's discretion.

A central adjudicating ground truth diagnosis panel is formed of experts in the area of stroke diagnosis and reviews all diagnostic information gathered by the investigational site as per the site's standard of care diagnostic workflow. The ground truth diagnosis panel is blinded to the output from the emu™ Brain Scanner and defines the 'ground truth' or 'reference standard' diagnosis for each patient to ensure accuracy and consistency. Integral to the ground truth diagnosis panel's consideration is the assessment by the core imaging lab, who similarly review all imaging provided by the investigational sites to ensure consistent input to the ground truth expert panel.

The result of the emu™ Brain Scan is compared to the ground truth diagnosis by a biostatistician to determine the accuracy of the emu™ Brain Scanner's diagnostic output (in terms of sensitivity and specificity) with the first output evaluated being intracranial haemorrhage detection in suspected stroke patients. The biostatistician then performs all statistical analyses against the study objectives in accordance with the Statistical Analysis Plan.

Being tested
Brain Scan
Medical subject headings
Stroke, Hemorrhagic Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Brain ScanDiagnostic test

    The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head.

    The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues.

Study groups in NCT06999122
Study groupRoleWhat they receive
Intracranial Haemorrhage Group ANot described
Receives: Diagnostic Test: Brain Scan
Other Group BGroup B includes all patients enrolled in the study ultimately diagnosed with a condition other than intracranial haemorrhage, including ischaemic stroke, transient ischaemic attack, or any of a variety of stroke mimicking conditions.
Receives: Diagnostic Test: Brain Scan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Demonstrate haemorrhage detection sensitivity >80% and specificity >80%

    Measured: <30 minutes from acute baseline CT/MRI

Secondary outcomes (4)
  1. Demonstrate the time to complete an emu™ Brain Scan is <15 minutes

    Measured: <30 minutes from acute baseline CT/MRI

  2. Evaluate safety of the device

    Measured: <30 minutes from acute baseline CT/MRI

  3. Evaluate usability of the device

    Measured: <30 minutes from acute baseline CT/MRI

  4. Evaluate device deficiencies

    Measured: <30 minutes from acute baseline CT/MRI

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 May 2025
  2. Study start26 Mar 2025
  3. Primary completion1 Nov 2026 (estimated)
  4. Study completion28 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06999122
Sponsor's protocol ID
EMV-CIP-03
Status last verified
Jul 2026
First submitted
13 May 2025
Last updated
27 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke and Hemorrhagic Stroke, run by EMVision Medical Devices Ltd at 8 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Christian Wight, PhD (61 (0) 490 109 797, cwight@emvision.com.au), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Demonstrate haemorrhage detection sensitivity >80% and specificity >80% (time frame: <30 minutes from acute baseline CT/MRI). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT06999122 | AzTrials